CHICAGO June 1, 2007 GlaxoSmithKline Oncology (GSK), in support of The American Society of Clinical Oncology (ASCO) and The ASCO Foundation, proudly announce today the creation of the Gianni Bonadonna Breast Cancer Award and Fellowship as a tribute to Dr. Bonadonnas outstanding contributions in the field of cancer research. The annual Award and Fellowship will acknowledge clinical or translational researchers of merit in the field of breast cancer and enable emerging investigators to undertake new patient-oriented research under the mentorship of the awardees. The new Award, which is supported by a multi-year grant in excess of one million dollars from GSK, will be unveiled at the ASCO Annual Meeting in Chicago and the first awardee will be announced at the 2007 ASCO Breast Cancer Symposium in September.
Dr. Gianni Bonadonna, Chair for the Committee on Prospective Clinical Trials at the Istituto Nazionale Tumori in Milan, Italy, is one of the most important figures in modern-day medical oncology. His significant achievements during a long esteemed career include his ground-breaking research in adjuvant treatment of breast cancer and the development of the combination chemotherapy regimen that remains the gold-standard treatment for Hodgkins disease today.
GSK is delighted and privileged to support ASCO and The ASCO Foundation on this new award that honors the legacy of one of the giants of medical oncology, said Paolo Paoletti, MD, Senior Vice President of the Oncology Medicine Development Center at GlaxoSmithKline. Dr. Bonadonna is an exceptional scientist, clinician and humanitarian. His revolutionary and courageous approaches to early stage cancer research opened up new avenues for the treatment of breast cancer, resulting in improved standards of care and longer lives for thousands of patients. His tangible impact on the progress we have made in cancer research continues to be felt today.
About the Gianni Bonadonna Breas
'"/>
Contact: Stephanie Gardner
stephanie.gardner@toniclc.com
44-207-798-9900
GAEA Initiative
1-Jun-2007